The pilot study provides “a good illustration of how AI can be an augmentation to our current processes,” Thomas Maddox says.

Without changes, including initiatives that help everyone at risk, past progress in slowing IHD’s damage may be further ...

The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...

Differences in various efficiency metrics were modest, but “minutes matter in stroke,” Shyam Prabhakaran says.

More than one in 10 patients with no coronary calcium had noncalcified plaque, putting them at greater risk for MACE.

Recommendations around dosing, duration, and patient-specific options are woven into the fabric of the scientific statement.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

A new statement makes the case for identifying recruits at risk of sudden cardiac death and older personnel at risk of CVD.

It’s critical to focus on treatment intensification, and not just initiation, in high-risk patients, Ambarish Pandey says.

In addition to giving patients standard verbal breath-holding instructions, the segment offers them an idea of what to expect ...

The FLASH protocol, associated with less radiation than a CAC scan, should be used more often in this cohort, a researcher ...